ABCL earnings date and last-quarter result: last quarter beat, P/E -11.94. Updated 2026-07-23.
AbCellera Biologics (ABCL) Research Hub
AbCellera Biologics (ABCL) trades on NASDAQ, CA in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 12.08 USD (+2.20%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -11.94, market cap 1.79B. This hub links to the full technical, earnings and options research available for ABCL.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, CA |
| Last close | 12.08 USD (+2.20%) |
| 52-week range | 4.98 USD – 15.02 USD |
| Trend regime | Range |
| 14-day RSI | 40.6 (Bearish) |
| Trailing P/E | -11.94 |
| Market cap | 1.79B |
| Dividend yield | 0.00% |
Available research for ABCL
Covered Call on ABCL: how it works, illustrative setup around the real 12.08 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ABCL: how it works, illustrative setup around the real 12.08 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ABCL: how it works, illustrative setup around the real 12.08 USD price, max profit/loss, breakeven and when to use it. Educational.
ABCL technical analysis: range, last 12.08 USD, RSI 40.6, 52w range 4.98 USD–15.02 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is ABCL in?
AbCellera Biologics (ABCL) is classified under Healthcare (Biotechnology), listed on NASDAQ, CA.
Is ABCL in an uptrend or downtrend?
As of 2026-10-26, ABCL is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ABCL's trailing P/E ratio?
ABCL's trailing P/E is -11.94, with a market cap of 1.79B. See the earnings research page for full valuation detail.